| scholarly article | Q13442814 |
| P50 | author | Nikolaus Marx | Q112515387 |
| P2093 | author name string | P Libby | |
| A D Luster | |||
| M N Sarafi | |||
| R M Ransohoff | |||
| J Plutzky | |||
| F Mach | |||
| A Sauty | |||
| J H Leung | |||
| P2860 | cites work | Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins | Q24300179 |
| HuMig: a new human member of the chemokine family of cytokines | Q24324494 | ||
| Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes | Q24336187 | ||
| Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells | Q24563090 | ||
| Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3 | Q24647146 | ||
| Protease inhibitors block lipopolysaccharide induction of tissue factor gene expression in human monocytic cells by preventing activation of c-Rel/p65 heterodimers | Q28238970 | ||
| Mechanism of action of fibrates on lipid and lipoprotein metabolism | Q28288187 | ||
| Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo | Q28371943 | ||
| Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta | Q28379553 | ||
| 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma | Q29615221 | ||
| An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) | Q29615693 | ||
| Chemokines--chemotactic cytokines that mediate inflammation | Q29616433 | ||
| A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation | Q29619212 | ||
| PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines | Q29620217 | ||
| The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation | Q29620219 | ||
| A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response | Q33857617 | ||
| Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase | Q33886831 | ||
| Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro | Q35753181 | ||
| A unique palindromic element mediates gamma interferon induction of mig gene expression | Q36645205 | ||
| Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo | Q40908023 | ||
| The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. | Q40964781 | ||
| A complex element regulates IFN-gamma-stimulated monocyte chemoattractant protein-1 gene transcription | Q41005077 | ||
| Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor | Q41105715 | ||
| The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones | Q41229841 | ||
| Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter | Q41565223 | ||
| PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells | Q42267879 | ||
| Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. | Q42536498 | ||
| Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2. | Q47994257 | ||
| Regulation of human IP-10 gene expression in astrocytoma cells by inflammatory cytokines. | Q55477373 | ||
| PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease | Q74598459 | ||
| p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha | Q77483953 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 6503-6508 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells | |
| P478 | volume | 164 |
| Q44198194 | 15-Deoxy-D12,14-prostaglandin J2 inhibits CX3CL1/fractalkine expression in human endothelial cells |
| Q44601893 | 15-Deoxy-delta 12,14-prostaglandin J2 inhibits the expression of granulocyte-macrophage colony-stimulating factor in endothelial cells stimulated with lipopolysaccharide |
| Q33746963 | A PPARγ-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis |
| Q36536205 | A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes |
| Q47953655 | Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. |
| Q36634314 | Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques |
| Q37211800 | Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease |
| Q40610269 | Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients |
| Q35298513 | Anti-inflammatory properties of lipid oxidation products |
| Q36611745 | Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells |
| Q35023612 | Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets |
| Q44590445 | Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits |
| Q36458462 | Bexarotene in the treatment of cutaneous T-cell lymphoma |
| Q80432110 | CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages |
| Q58246532 | Chemokines and atherosclerosis |
| Q35747641 | Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes |
| Q42497785 | Constitutive and regulated expression and secretion of interferon-gamma-inducible protein 10 (IP-10/CXCL10) in human adipocytes |
| Q24684054 | Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation |
| Q58229736 | Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology |
| Q57067440 | Diet-Modulated Lipoprotein Metabolism and Vascular Inflammation Evaluated by F-fluorodeoxyglucose Positron Emission Tomography |
| Q45987160 | Dietary n-3 fatty acids attenuate cardiac allograft vasculopathy via activating peroxisome proliferator-activated receptor-gamma. |
| Q51042965 | Early increase in alveolar macrophage prostaglandin 15d-PGJ2 precedes neutrophil recruitment into lungs of cytokine-insufflated rats. |
| Q44633202 | Effect of 15-deoxy-Δ12,14-prostaglandin J2 on IL-1β-induced expression of epithelial neutrophil-activating protein-78 in human endothelial cells |
| Q40251913 | Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2). |
| Q43108533 | Effect of rosiglitazone on cisplatin-induced nephrotoxicity |
| Q40208687 | Effects of flavonoids on the expression of the pro-inflammatory response in human monocytes induced by ligation of the receptor for AGEs |
| Q35044388 | Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation |
| Q33642053 | Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. |
| Q37624930 | Endothelium as a gatekeeper of fatty acid transport |
| Q57373134 | Fatty Acid Regulation of Gene Transcription |
| Q35115458 | Free Radicals and Lipid Signaling in Endothelial Cells |
| Q35014033 | HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells |
| Q40652063 | High Glucose-Induced Expression of Proinflammatory Cytokine and Chemokine Genes in Monocytic Cells |
| Q61638147 | High serum levels of CXC chemokine ligand 10 in untreated essential hypertension |
| Q81683808 | Hormone regulation of microglial cell activation: relevance to multiple sclerosis |
| Q34871916 | Immunomodulatory actions of leptin |
| Q46740652 | Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. |
| Q46626095 | Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease |
| Q36202581 | Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists |
| Q39797885 | Influence of apple polyphenols on inflammatory gene expression |
| Q37557746 | Influence of conjugated linoleic acids on functional properties of vascular cells |
| Q39980108 | Influenza A virus abrogates IFN-gamma response in respiratory epithelial cells by disruption of the Jak/Stat pathway. |
| Q36890231 | Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease |
| Q43059312 | Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells |
| Q33967999 | Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. |
| Q34962291 | Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions |
| Q36510633 | Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction |
| Q34348648 | Interferon-gamma induces retinoic acid-inducible gene-I in endothelial cells |
| Q33243924 | Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis |
| Q36393212 | Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer |
| Q42135532 | Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. |
| Q40043011 | NF-kappaB-dependent synergistic regulation of CXCL10 gene expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines |
| Q33815718 | NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway |
| Q34309219 | Network analysis identifies a putative role for the PPAR and type 1 interferon pathways in glucocorticoid actions in asthmatics |
| Q35670502 | Novel pituitary ligands: peroxisome proliferator activating receptor-gamma |
| Q36733873 | Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors |
| Q33644094 | Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis |
| Q34024668 | Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance |
| Q42263066 | Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial |
| Q40778017 | Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus |
| Q21342822 | PPAR-gamma: Therapeutic Potential for Multiple Sclerosis |
| Q26863678 | PPAR-γ -- a possible drug target for complicated pregnancies |
| Q48247479 | PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia. |
| Q43872427 | PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells |
| Q37002797 | PPARalpha and PPARgamma effectively protect against HIV-induced inflammatory responses in brain endothelial cells |
| Q36154953 | PPARalpha in atherosclerosis and inflammation |
| Q35768913 | PPARgamma as a new therapeutic target in inflammatory bowel diseases |
| Q36791361 | PPARs and molecular mechanisms of transrepression |
| Q24642728 | PPARs and the cardiovascular system |
| Q36889164 | PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? |
| Q38132128 | PPARγ Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us? |
| Q37777055 | PPARγ and chronic kidney disease |
| Q37115840 | Pathophysiological roles of microvascular alterations in pulmonary inflammatory diseases: possible implications of tumor necrosis factor-alpha and CXC chemokines |
| Q27022369 | Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity |
| Q33816291 | Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage |
| Q43760306 | Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells |
| Q44247093 | Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis |
| Q34492831 | Peroxisome proliferator-activated receptor gamma and atherosclerosis |
| Q57975195 | Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease |
| Q47739408 | Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair |
| Q57244326 | Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells |
| Q34365179 | Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts |
| Q40147302 | Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells |
| Q44060078 | Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis |
| Q44848225 | Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element |
| Q37861955 | Peroxisome proliferator-activated receptors and atherosclerosis. |
| Q35173859 | Peroxisome proliferator-activated receptors and the cardiovascular system |
| Q34290988 | Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update |
| Q36510464 | Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications |
| Q35539448 | Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function |
| Q40343418 | Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells |
| Q38469591 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging |
| Q33406281 | Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation |
| Q38112106 | Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. |
| Q45309412 | Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells |
| Q42008239 | Protective Actions of PPAR-gamma Activation in Renal Endothelium |
| Q34178976 | Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1 |
| Q46117356 | Rat chemokine CXCL11: structure, tissue distribution, function and expression in cardiac transplantation models |
| Q37114625 | Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation |
| Q35027759 | Regulation of chemokine expression in atherosclerosis |
| Q34724089 | Role of CXCL1 in tumorigenesis of melanoma. |
| Q27000731 | Role of lipotoxicity in endothelial dysfunction |
| Q34992771 | Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases |
| Q41570973 | Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation |
| Q43239098 | Separation, characterization and dose-effect relationship of the PPARgamma-activating bio-active constituents in the Chinese herb formulation 'San-Ao decoction'. |
| Q35101529 | The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria |
| Q37337997 | The Role of PPARs in the Endothelium: Implications for Cancer Therapy |
| Q35212555 | The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis |
| Q90235289 | The protective effect of myo-inositol on human thyrocytes |
| Q34838209 | The role of PPARs in atherosclerosis |
| Q34207434 | The role of chemokines in atherosclerosis |
| Q40858470 | The role of the Th1 chemokine CXCL10 in vitiligo |
| Q97076303 | The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review |
| Q53580895 | Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. |
| Q36632030 | Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism |
| Q41681579 | Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies |
| Q45281571 | Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism |
| Q34075896 | Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation |
| Q46475661 | Upregulation of LPS-induced chemokine KC expression by 15-deoxy-delta12,14-prostaglandin J2 in mouse peritoneal macrophages |
| Q79387298 | Upregulation of MIP-2 (CXCL2) expression by 15-deoxy-Delta(12,14)-prostaglandin J(2) in mouse peritoneal macrophages |
| Q33959265 | VLDL hydrolysis by hepatic lipase regulates PPARδ transcriptional responses |
| Q34790065 | Vascular effects of GI262570X (PPAR-gamma agonist) in the brown adipose tissue of Han Wistar rats: a review of 1-month, 13-week, 27-week and 2-year oral toxicity studies |
Search more.